Stock Events

Stock Events

180 Life Sciences 

$7.04
118
-$0.57-7.49% Friday 20:00
+$0.26+3.69%Friday 23:59Pre-market

Statistics

Day High
7.24
Day Low
6.29
52W High
17.75
52W Low
0.6578
Volume
11,633,983
Avg. Volume
9,833,114
Mkt Cap
0
P/E Ratio
-
Dividend Yield
-
Dividend
-

Earnings

25FebExpected
Q2 2024
Q3 2024
Q4 2024
Q1 2025
Q2 2025
Q3 2025
Q4 2025
-0.85
-0.52
-0.18
0.15
Expected EPS
N/A
Actual EPS
N/A

Financials

-Profit Margin
Unprofitable
2019
2020
2021
2022
2023
2024
0Revenue
-14.18MNet Income

Analyst Ratings

9.00Average Price Target
The highest estimate is 9.00.
From 1 ratings within the last 6 months. This is not an investment recommendation.
Buy
0%
Hold
100%
Sell
0%

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
CRISPR Therapeutics
CRSP
Mkt Cap5.25B
CRISPR Therapeutics is involved in gene editing, a cutting-edge area of biotechnology that could compete with 180 Life Sciences' novel therapeutic approaches.
Editas Medicine
EDIT
Mkt Cap500.29M
Editas Medicine operates in the genome editing space, directly competing with 180 Life Sciences in developing treatments for diseases with unmet medical needs.
Intellia Therapeutics
NTLA
Mkt Cap1.99B
Intellia Therapeutics is another key player in the CRISPR/Cas9 technology sector, potentially competing with 180 Life Sciences in the field of genetic and autoimmune diseases.
Vertex Pharmaceuticals
VRTX
Mkt Cap123.19B
Vertex Pharmaceuticals focuses on creating transformative medicines for people with serious diseases, which aligns with 180 Life Sciences' mission, making them competitors.
Regeneron Pharmaceuticals
REGN
Mkt Cap69.67B
Regeneron Pharmaceuticals is known for its innovation in biotechnology, competing with 180 Life Sciences in developing novel therapeutics for various diseases.
Alnylam Pharmaceuticals
ALNY
Mkt Cap39.89B
Alnylam Pharmaceuticals is a leader in RNAi therapeutics, competing with 180 Life Sciences in the development of novel treatments for genetic and other diseases.
Biomarin Pharmaceutical
BMRN
Mkt Cap11.43B
BioMarin Pharmaceutical focuses on enzyme replacement therapies and other innovative treatments for rare genetic diseases, competing with 180 Life Sciences in the rare disease space.
Sarepta Therapeutics
SRPT
Mkt Cap2B
Sarepta Therapeutics is focused on the discovery and development of RNA-based therapeutics, competing with 180 Life Sciences in the development of innovative treatments for diseases.

About

1180 Life Sciences Corp., a clinical-stage biotechnology company, develops therapeutics for unmet medical needs in chronic pain, inflammation, fibrosis, and other inflammatory diseases. Its product development platforms include fibrosis and anti-tumor necrosis factor (anti-TNF) platform, which is under Phase IIb clinical trials that focuses on fibrosis and Anti-TNF; Synthetic Cannabidiol (CBD) Analogs platform, which is under preclinical trials that are man-made derivatives of CBD; and a7nAChR platform, an immune suppressive, which is under preclinical trails that focuses on alpha 7 nicotinic acetylcholine receptor. The company was incorporated in 2016 and is headquartered in Palo Alto, California.
Show more...
CEO
Mr. Lloyd Blair Jordan L.L.B., M.B.A.
Employees
4
Country
United States
ISIN
US68236V1044

Listings

F
DE
L270.F
BOATS
BOATS
ETHZ.BOATS
XNAS
US
FRMM

0 Comments

Share your thoughts

FAQ

What is 180 Life Sciences stock price today?▼
The current price of ATNF is $7.04 USD — it has decreased by -7.49% in the past 24 hours. Watch 180 Life Sciences stock price performance more closely on the chart.
What is 180 Life Sciences stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on XNAS exchange 180 Life Sciences stocks are traded under the ticker ATNF.
Is 180 Life Sciences stock price growing?▼
ATNF stock has risen by +0% compared to the previous week, the month change is a +0% rise, over the last year 180 Life Sciences has showed a +687.47% increase.
What is 180 Life Sciences revenue for the last year?▼
180 Life Sciences revenue for the last year amounts to 0 USD.
What is 180 Life Sciences net income for the last year?▼
ATNF net income for the last year is -14.18M USD.
How many employees does 180 Life Sciences have?▼
As of July 15, 2026, the company has 4 employees.
In which sector is 180 Life Sciences located?▼
180 Life Sciences operates in the Health & Wellness sector.
When did 180 Life Sciences complete a stock split?▼
The last stock split for 180 Life Sciences was on February 28, 2024 with a ratio of 1:19.
Where is 180 Life Sciences headquartered?▼
180 Life Sciences is headquartered in Palo Alto, United States.